Skip to main content
SpringerLink
Log in

A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reference

  1. Masamichi M, Naoki K, Yoko U et al (2017) Gilteritinib, a FLT3/AXL inhibitor, shows anti-leukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investig New Drugs 35:556–565

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Kokura Memorial Hospital, 3-2-1,Asano Kokura-kita, Kitakyushu, Japan

    Takashi Onaka, Aiko Kato-Ogura, Yasuyuki Otsuka, Fumie Iwai & Akihito Yonezawa

Authors
  1. Takashi Onaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aiko Kato-Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuyuki Otsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fumie Iwai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akihito Yonezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TO managed the patient and wrote the manuscript. AO, YO, FI, and AY coordinated and approved the final version of the manuscript.

Corresponding author

Correspondence to Takashi Onaka.

Ethics declarations

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Informed consent was obtained from the patient in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onaka, T., Kato-Ogura, A., Otsuka, Y. et al. A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer. Ann Hematol 101, 457–458 (2022). https://doi.org/10.1007/s00277-021-04516-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04516-w

Search

Navigation